Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen announced that the FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy (SMA). The designation is based on Phase 1b data showing that children with SMA who had suboptimal responses to prior gene therapy experienced slowing of neurodegeneration and clinically meaningful improvements in motor function, including gaining new milestones like sitting and walking. Salanersen is an investigational antisense oligonucleotide with potential for once-yearly dosing, licensed from Ionis Pharmaceuticals.
Key figures
- Drug Name
- salanersen
- Phase Of Trial
- Phase 1b
- Nfl reduction
- 75%
- Participants treated
- 24
- Dose evaluated phase3
- 80 mg
- Participants new milestones
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.